KLRG1 and type 1 diabetes mellitus: On the same line, in the follow-up study of the T1DAL trial [99], which treated recent-onset T1D patients with the immunomodulator alefacept, RNAseq was used to stratify patients as responders or non-responders, and allowed the identification within the responder group of a cluster of memory cells exhibiting an exhausted phenotype marked by TIGIT and KLRG1 expression.